Both doses of Celgene Corp.'s ozanimod tested in the Phase III SUNBEAM clinical trial significantly beat the multiple sclerosis standard of care interferon on three different measures of efficacy, but safety may be the most important differentiator for the closely-watched drug.
Investors are keeping their eyes on Celgene's sphingosine-1 phosphate (S1P) receptor modulator, because it has the potential to be a...







